Trial Profile
Phase II/III, Multicenter, Double-Masked, Randomized, Parallel Group, Dose Ranging, Controlled Trial of Efficacy and Tolerance of Nova22007 (Cyclosporine A [CSA] 0.05% & 0.1% Ophthalmic Cationic Emulsion) Versus Vehicle in Patients With VKC
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 26 Oct 2023
Price :
$35
*
At a glance
- Drugs Ciclosporin (Primary)
- Indications Allergic conjunctivitis
- Focus Registrational; Therapeutic Use
- Acronyms NOVATIVE
- Sponsors Santen S.A.S.
- 12 Oct 2023 Primary endpoint (Overall Rating of Objective Symptoms of VKC in Period I) has not been met, according to Results published in the Clinical Therapeutics.
- 12 Oct 2023 Primary endpoint (Overall Rating of Subjective Symptoms of VKC in Period I) has not been met, according to Results published in the Clinical Therapeutics.
- 12 Oct 2023 Results published in the Clinical Therapeutics